피부사상균성 손발톱진균증 치료 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the dermatophytic onychomycosis treatment market size is expected to grow from USD 2.40 billion in 2025 to USD 2.51 billion in 2026 and is forecast to reach USD 3.14 billion by 2031 at 4.55% CAGR over 2026-2031.

This report is Segmented by Medication (Terbinafine, Itraconazole, Fluconazole, Ciclopirox, Amorolfine, Others), Product Type (Tablets, Nail Paints), Treatment Route (Oral, Topical), Treatment Type (Prescription, Over-The-Counter), Distribution Channel (Retail Pharmacies, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Dermatophytic Onychomycosis Treatment Market Trends and Insights

Rising Dermatophyte Burden in Aging and Diabetic Populations

The dermatophytic onychomycosis treatment market is most firmly supported by diabetes-linked demand, because diabetes affected 589 million people worldwide in 2024 and many of these patients face conditions that raise fungal nail infection risk and complicate treatment. The same evidence base shows that diabetic individuals face up to 2.8 times greater odds of developing onychomycosis than non-diabetic individuals, which keeps this patient pool central to long-run therapy demand. Aging adds a second structural layer, because geriatric patients face 4.7 times greater onychomycosis risk than the general population as nail growth slows and cumulative dermatophyte exposure rises over time. The effect on the dermatophytic onychomycosis treatment market is broader than simple case growth, because these patients often need longer treatment, closer follow-up, and more careful management when neuropathy, immune dysfunction, or poor nail perfusion are present. Clinical burden also matters beyond dermatology, because diabetic nail infection can feed into wound-care and podiatry management pathways, which expands the practical prescriber base for therapy. This makes the dermatophytic onychomycosis treatment market less dependent on cosmetic demand alone and more connected to chronic disease management in older and higher-risk populations.

Growing Use of Advanced Nail Penetration Technologies

The dermatophytic onychomycosis treatment market is also being lifted by better topical delivery, because poor penetration through the keratin nail plate had long limited topical efficacy and kept oral therapy in a stronger position. In a 2024 randomized clinical trial, ciclopirox 8% with hydroxypropyl chitosan showed 3.25-fold higher permeability than older reference lacquer formulations, which directly supports the newer growth profile for premium topical formats. Separate laboratory work showed that microporation combined with optimized gel vehicles further improved drug flux across the nail plate, which strengthens the case for technology-led differentiation in this category. The commercial proof point became clearer in 2025, when Moberg Pharma stated that Terclara, a water-soluble terbinafine nail lacquer using HPCH technology, achieved 76% mycological cure in Phase III trials and quickly became the market leader in Norway after launch. These gains matter for the dermatophytic onychomycosis treatment market because they improve the value proposition of topical treatment in mild-to-moderate disease and support OTC positioning in selected European markets. They also shift competitive advantage toward companies that own delivery intellectual property rather than toward companies competing only on generic price.

Long Treatment Duration Depresses Adherence and Persistence

The dermatophytic onychomycosis treatment market still faces a basic adherence problem, because visible nail improvement arrives slowly even when fungal control is achieved earlier in the course of therapy. The user input showed that oral terbinafine regimens commonly run for 3 to 6 months in toenails, while topical monotherapy can extend to 9 to 12 months for a single affected toenail, which makes persistence difficult in routine care. This weighs on the dermatophytic onychomycosis treatment market because many patients judge progress by cosmetic clearing rather than by mycological response, and that delay weakens motivation to continue treatment. The burden is especially relevant in elderly and diabetic populations, where longer treatment windows overlap with polypharmacy, mobility limits, and lower tolerance for repeated follow-up. Digital reminders and teledermatology follow-up can help, but the dermatophytic onychomycosis treatment market does not yet benefit fully from these tools because adoption remains uneven across the highest-risk patient groups. Until treatment timelines become easier to manage or easier to explain, adherence drag will continue to limit realized outcomes and branded product persistence in daily practice.

Other drivers and restraints analyzed in the detailed report include:

1. Underdiagnosis Creating Latent Treatment Conversion Opportunity
2. Recurrence Management Driving Repeat Prescriptions and Combination Therapy Uptake
3. Therapeutic Resistance and Biofilm Persistence Reduce Cure Confidence

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Terbinafine held 42.31% of segment revenue in 2025, which kept it as the largest medication in the dermatophytic onychomycosis treatment market because it remains the standard first-line systemic option for dermatophyte-led infection. Its lead reflects 3 reinforcing factors, guideline familiarity, broad generic supply, and strong clinical acceptance in moderate-to-severe disease where deeper fungal involvement limits what topical therapy can do. In cost-sensitive settings this leadership is still durable, because generic oral therapy fits the reimbursement and pricing logic that shapes a large share of established prescribing pathways. Even so, the medication mix inside the dermatophytic onychomycosis treatment market is starting to change because reliance on a single first-line oral agent also creates exposure to resistance concerns and safety-related prescribing hesitation. That shift does not remove terbinafine from its leading position, but it does reduce the ease with which it can extend share from here, especially where resistant strains are entering routine clinical awareness.

Ciclopirox is the fastest-growing medication at a 6.38% CAGR through 2031, and that pace shows how formulation improvement is changing what older molecules can deliver in the dermatophytic onychomycosis industry. HPCH delivery technology has improved nail penetration, while clinical practice evidence in 2025 showed that combination ciclopirox-terbinafine therapy outperformed oral monotherapy in real-world records analyzed with artificial intelligence. That combination role matters, because it supports ciclopirox both as a standalone topical option in milder disease and as an adjunct in higher-risk or recurrent cases. Itraconazole continues to hold a defensive place for patients who cannot use terbinafine or who need an alternative oral path when resistance concerns are stronger. Fluconazole remains relevant in practice because of low cost and physician familiarity, even though its dermatophyte-specific profile is less compelling than terbinafine. Amorolfine keeps a useful weekly-application topical niche across Europe and Asia, which gives the dermatophytic onychomycosis treatment market a broader range of adherence-oriented options outside the U.S.

Tablets accounted for 57.24% of the dermatophytic onychomycosis treatment market size in 2025, reflecting the continuing need for oral systemic treatment in cases where disease depth and nail involvement reduce the expected effect of surface therapy. The tablet format also benefits from established physician habit, mature generic availability, and straightforward dosing that fits existing care pathways in dermatology, podiatry, and primary care. For many clinicians, tablets still define the core treatment backbone of the dermatophytic onychomycosis treatment market when disease is moderate or severe and rapid fungal suppression matters more than cosmetic preferences. That keeps the category durable, even while some patients and physicians prefer to avoid monitoring demands associated with systemic therapy. The leading position of tablets therefore remains grounded in clinical necessity rather than in format preference alone.

Nail paints are forecast to grow at a 5.52% CAGR through 2031, which makes them the most dynamic product format as improved delivery systems raise efficacy expectations in milder disease. The clearest validation came from Moberg Pharma, which reported 76% mycological cure for Terclara in Phase III trials compared with up to 42% for prior comparators. Those data matter because they turn nail paints from a lower-efficacy legacy format into a more credible treatment choice within the dermatophytic onychomycosis treatment market. Better cosmetic acceptance also supports this shift, since many patients are more willing to stay on a visible and non-systemic format when the performance tradeoff becomes less severe. The growth of nail paints therefore reflects both science and behavior, not just packaging format. As a result, the dermatophytic onychomycosis treatment market is likely to see a more balanced split between oral and advanced topical product forms over the forecast period.

Complete Report Scope:

• By Medication
  • Terbinafine
  • Itraconazole
  • Fluconazole
  • Ciclopirox
  • Amorolfine
  • Other Medication
• By Product Type
  • Tablets
  • Nail Paints
• By Treatment Route
  • Oral
  • Topical
• By Treatment Type
  • Prescription
  • Over-The-Counter
• By Distribution Channel
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores
  • Other Distribution Channels
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 38.22% of global revenue in 2025 and therefore remained the largest regional contributor to the dermatophytic onychomycosis treatment market share. The region's position rests on high disease prevalence, broad access to dermatology and podiatry care, and a mature formulary mix that includes both branded and generic antifungal options. The U.S. also shows the clearest treatment-conversion gap, because many diagnosed visits still do not progress to confirmatory testing or drug treatment, which leaves room for volume expansion if diagnosis improves. Europe follows with steadier expansion, supported by established prescription dermatology pathways, rising topical innovation, and a staggered regulatory pathway for efinaconazole across member states after the decentralized procedure was completed in 2024.

Asia-Pacific is the fastest-growing region, with the dermatophytic onychomycosis treatment market size in this geography projected to expand at a 6.65% CAGR through 2031. The region benefits from a combination that is harder to find in mature markets, rising diabetes burden, expanding private dermatology access, and wider use of government-backed telemedicine that helps underserved patients reach treatment pathways. Japan remains a key reference point because topical-first prescribing has historically been common among older patients who are less suitable for systemic treatment. Updated 2025 skin fungal disease guidance in Japan added new resistance information and stronger oral evidence, which is likely to make route choice more selective rather than uniformly topical-first. Kaken's launch of an authorized generic efinaconazole nail solution in Japan and its China development activity show how regional companies are using intra-Asian pathways to extend dermatology assets across multiple markets.

The Middle East and Africa and South America remain smaller contributors, but both are adding incremental demand to the dermatophytic onychomycosis treatment market as access improves. In MEA, GCC countries stand out for stronger OTC antifungal spending and consumer awareness, while South Africa offers the most structured pharmaceutical distribution base in sub-Saharan Africa. In South America, Brazil benefits from a growing private dermatology clinic network and broader prescription access, while more volatile reimbursement conditions in Argentina continue to favor generics over premium topical brands. Across both regions, wider online pharmacy use is helping reduce reliance on traditional brick-and-mortar constraints, which should gradually improve access for OTC and maintenance products.

1. Astellas Pharma
2. Bausch Health
3. Bayer
4. Cipla
5. Dr. Reddy's Laboratories
6. Galderma
7. GlaxoSmithKline
8. Janssen Global Services, LLC
9. Kaken Pharmaceutical Co., Ltd.
10. Medimetriks Pharmaceuticals, Inc.
11. Merck
12. Moberg Pharma
13. Novartis
14. Pfizer
15. Sanofi
16. Sun Pharmaceuticals Industries
17. Teva Pharmaceutical Industries
18. TheOTCLab B.V.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Dermatophyte Burden in Aging and Diabetic Populations
  • 4.2.2 Preference Shift Toward Topical Therapies With Better Cosmetic Acceptance
  • 4.2.3 Expanding Access To Specialist Dermatology and Retail Pharmacy Channels
  • 4.2.4 Growing Use of Advanced Nail Penetration Technologies
  • 4.2.5 Underdiagnosis Creating Latent Treatment Conversion Opportunity
  • 4.2.6 Recurrence Management Driving Repeat Prescriptions and Combination Therapy Uptake
• 4.3 Market Restraints
  • 4.3.1 Long Treatment Duration Depresses Adherence and Persistence
  • 4.3.2 Oral Antifungal Safety Concerns Limit High-Value Prescribing
  • 4.3.3 Limited Reimbursement and High Out-Of-Pocket Cost in Several Markets
  • 4.3.4 Therapeutic Resistance and Biofilm Persistence Reduce Cure Confidence
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Bargaining Power of Suppliers
  • 4.7.2 Bargaining Power of Buyers
  • 4.7.3 Threat of New Entrants
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Medication
  • 5.1.1 Terbinafine
  • 5.1.2 Itraconazole
  • 5.1.3 Fluconazole
  • 5.1.4 Ciclopirox
  • 5.1.5 Amorolfine
  • 5.1.6 Other Medication
• 5.2 By Product Type
  • 5.2.1 Tablets
  • 5.2.2 Nail Paints
• 5.3 By Treatment Route
  • 5.3.1 Oral
  • 5.3.2 Topical
• 5.4 By Treatment Type
  • 5.4.1 Prescription
  • 5.4.2 Over-The-Counter
• 5.5 By Distribution Channel
  • 5.5.1 Retail Pharmacies
  • 5.5.2 Online Pharmacies
  • 5.5.3 Drug Stores
  • 5.5.4 Other Distribution Channels
• 5.6 By Geography
  • 5.6.1 North America
    • 5.6.1.1 United States
    • 5.6.1.2 Canada
    • 5.6.1.3 Mexico
  • 5.6.2 Europe
    • 5.6.2.1 Germany
    • 5.6.2.2 United Kingdom
    • 5.6.2.3 France
    • 5.6.2.4 Italy
    • 5.6.2.5 Spain
    • 5.6.2.6 Rest of Europe
  • 5.6.3 Asia-Pacific
    • 5.6.3.1 China
    • 5.6.3.2 Japan
    • 5.6.3.3 India
    • 5.6.3.4 Australia
    • 5.6.3.5 South Korea
    • 5.6.3.6 Rest of Asia-Pacific
  • 5.6.4 Middle East and Africa
    • 5.6.4.1 GCC
    • 5.6.4.2 South Africa
    • 5.6.4.3 Rest of Middle East and Africa
  • 5.6.5 South America
    • 5.6.5.1 Brazil
    • 5.6.5.2 Argentina
    • 5.6.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Astellas Pharma Inc.
  • 6.3.2 Bausch Health Companies Inc.
  • 6.3.3 Bayer AG
  • 6.3.4 Cipla Limited
  • 6.3.5 Dr. Reddy's Laboratories Ltd.
  • 6.3.6 Galderma S.A.
  • 6.3.7 GlaxoSmithKline plc
  • 6.3.8 Janssen Global Services, LLC
  • 6.3.9 Kaken Pharmaceutical Co., Ltd.
  • 6.3.10 Medimetriks Pharmaceuticals, Inc.
  • 6.3.11 Merck & Co., Inc.
  • 6.3.12 Moberg Pharma AB
  • 6.3.13 Novartis AG
  • 6.3.14 Pfizer Inc.
  • 6.3.15 Sanofi
  • 6.3.16 Sun Pharmaceutical Industries Ltd.
  • 6.3.17 Teva Pharmaceutical Industries Ltd.
  • 6.3.18 TheOTCLab B.V.

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment